Renal Tumors Classification, Biology, and Banking Study

About this Study

A primary goal of the committee is to refine the current classification schema to better stratify patients into risk-appropriate treatment groups.  Additional clinical and molecular factors are now known to be predictive of outcome.  This study will therefore serve as the infrastructure for rapid and reliable acquisition of the results of proven prognostic markers (histopathology, disease stage, chromosome 1p and 16q allelic status (LOH) and response evaluation (diagnostic pulmonary imaging). 

Sponsor Protocol ID:ARENO3B2
IRB Number:2006-0069
Actively Enrolling
Interventional
Early Phase 1
May 28, 2019
Eligibility Criteria
64 years old
Both Male and Female
Yes
Yes
No

Inclusion Criteria
  • Renal tumor diagnosis: Nephroblastic tumors, Mesoblastic Nephroma, Clear Cell Sarcoma, Rhabdoid Tumor, Renal Eithelioid Tumors of Childhood, Angiolipoma, and Ossifying renal tumor of infancy

  • Extrarenal tumor

  • Patients must be 30 years old at the time of diagnosis.

  • All patients and/or their parents or legal guardians must sign a written informed consent. All institutional, FDA, and NCI requirements for human studies must be met.


Exclusion CriteriaNone

Categories Click category to view its trials.
Cancer
Pediatrics
Participating Locations
Children’s of Mississippi Hospital - Blair E. Batson Tower
Children's of Mississippi Center for Cancer and Blood Disorders
Contact Information
Contact Name: Leslie Johnson
Phone Number: 601-815-3067
Email: lnjohnson@umc.edu
Principal Investigator:Benjamin Stronach
How to participate in our Clinical Trials